Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registry.
CGRP
Daily headache
Elderly
Fibromyagia
Galcanezumab
Migraine
Monoclonal antibody
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
11
10
2023
accepted:
09
11
2023
medline:
27
11
2023
pubmed:
23
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population observed in real-world setting. To describe the long-term effectiveness and tolerability of galcanezumab in clinical practice in patients excluded from RCTs. Multicenter prospective cohort study of consecutive patients with chronic and high-frequency episodic migraine (HFEM) with prior failure to three or more migraine preventive drugs, treated with galcanezumab and followed up for 12 months. We enrolled 1055 patients, aged 50 (IQR: 42-58), 82.9% female, 76.4% chronic migraine, 69% with at least one exclusion criteria for RCTs, including age > 65 (n = 121), concomitant use of onabotulinumtoxinA (n = 185), daily headache at baseline (n = 347), chronic painful syndromes (n = 206), fibromyalgia (n = 101) or treatment resistance (n = 957). The median number of prior preventive treatments was 4 (IQR: 3-5). The retention rate was 90.8%, 76.8% and 71.4% at 3, 6 and 12 months. The main reasons for treatment discontinuation were lack of effectiveness (21.1%) and inadequate tolerability (6.6%). The 30%, 50% and 75% responder rates were 62.6%, 49.8% and 24.2% between weeks 8-12; 60.9%, 48.8% and 24.6% between weeks 20-24; and 59.7%, 48.3% and 24.6% between weeks 44-48. Daily headache at baseline (OR: 0.619; 95%CI: 0.469-0.817) and patient's age (OR: 1.016; 95%CI: 1.005-1.026) were associated with 50% response at weeks 20-24. The variables that were associated with a higher reduction of headache days between weeks 20-24 were patient's age (0.068; 95% CI: 0.018-0.119) and headache days per month at baseline (0.451; 95% CI: 0.319-0.583), while psychiatric comorbidity (-1.587; 95% CI: -2.626-0.538) and daily headache at baseline (-2.718; 95% CI: -4.58-0.869) were associated with fewer reduction in the number of headache days between weeks 20-24. This study provides class III evidence of effectiveness and tolerability of galcanezumab in patients with HFEM and CM with comorbidities that would result in exclusion of the pivotal RCTs. Nonetheless, the clinical results over a 12-month period were similar to the efficacy observed in randomized controlled trials. Few patients discontinued the drug due to inadequate tolerability.
Sections du résumé
BACKGROUND
BACKGROUND
Galcanezumab has shown efficacy and effectiveness in the treatment of episodic and chronic migraine (CM), however, the population represented in randomized clinical trials (RCTs) differs from the population observed in real-world setting. To describe the long-term effectiveness and tolerability of galcanezumab in clinical practice in patients excluded from RCTs.
METHODS
METHODS
Multicenter prospective cohort study of consecutive patients with chronic and high-frequency episodic migraine (HFEM) with prior failure to three or more migraine preventive drugs, treated with galcanezumab and followed up for 12 months.
RESULTS
RESULTS
We enrolled 1055 patients, aged 50 (IQR: 42-58), 82.9% female, 76.4% chronic migraine, 69% with at least one exclusion criteria for RCTs, including age > 65 (n = 121), concomitant use of onabotulinumtoxinA (n = 185), daily headache at baseline (n = 347), chronic painful syndromes (n = 206), fibromyalgia (n = 101) or treatment resistance (n = 957). The median number of prior preventive treatments was 4 (IQR: 3-5). The retention rate was 90.8%, 76.8% and 71.4% at 3, 6 and 12 months. The main reasons for treatment discontinuation were lack of effectiveness (21.1%) and inadequate tolerability (6.6%). The 30%, 50% and 75% responder rates were 62.6%, 49.8% and 24.2% between weeks 8-12; 60.9%, 48.8% and 24.6% between weeks 20-24; and 59.7%, 48.3% and 24.6% between weeks 44-48. Daily headache at baseline (OR: 0.619; 95%CI: 0.469-0.817) and patient's age (OR: 1.016; 95%CI: 1.005-1.026) were associated with 50% response at weeks 20-24. The variables that were associated with a higher reduction of headache days between weeks 20-24 were patient's age (0.068; 95% CI: 0.018-0.119) and headache days per month at baseline (0.451; 95% CI: 0.319-0.583), while psychiatric comorbidity (-1.587; 95% CI: -2.626-0.538) and daily headache at baseline (-2.718; 95% CI: -4.58-0.869) were associated with fewer reduction in the number of headache days between weeks 20-24.
CONCLUSION
CONCLUSIONS
This study provides class III evidence of effectiveness and tolerability of galcanezumab in patients with HFEM and CM with comorbidities that would result in exclusion of the pivotal RCTs. Nonetheless, the clinical results over a 12-month period were similar to the efficacy observed in randomized controlled trials. Few patients discontinued the drug due to inadequate tolerability.
Identifiants
pubmed: 37993795
doi: 10.1186/s10194-023-01690-2
pii: 10.1186/s10194-023-01690-2
pmc: PMC10666410
doi:
Substances chimiques
galcanezumab
55KHL3P693
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
157Informations de copyright
© 2023. The Author(s).
Références
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Neurology. 2023 Sep 12;101(11):482-488
pubmed: 37072224
Lancet Neurol. 2020 Oct;19(10):814-825
pubmed: 32949542
J Headache Pain. 2023 Jun 2;24(1):63
pubmed: 37268904
Pain Ther. 2021 Dec;10(2):809-826
pubmed: 33880725
J Headache Pain. 2022 Nov 1;23(1):138
pubmed: 36316648
JAMA Neurol. 2018 Sep 1;75(9):1080-1088
pubmed: 29813147
J Headache Pain. 2023 Mar 16;24(1):26
pubmed: 36927366
Contemp Clin Trials Commun. 2020 Nov 26;20:100684
pubmed: 33319119
J Headache Pain. 2023 Oct 30;24(1):144
pubmed: 37899428
Cephalalgia. 2020 Sep;40(10):1026-1044
pubmed: 32722936
Cephalalgia. 2023 Mar;43(3):3331024231152169
pubmed: 36786548
J Headache Pain. 2020 Jun 16;21(1):76
pubmed: 32546227
Pharmaceuticals (Basel). 2023 Jun 27;16(7):
pubmed: 37513846
Cephalalgia. 2022 Oct;42(11-12):1099-1115
pubmed: 35514209
J Biopharm Stat. 2009 Jul;19(4):672-84
pubmed: 20183433
Eur J Neurol. 2023 Jan;30(1):224-234
pubmed: 36097739
Cephalalgia. 2018 Jul;38(8):1442-1454
pubmed: 29848108
Sci Rep. 2023 Sep 8;13(1):14825
pubmed: 37684346
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Neurology. 2018 Dec 11;91(24):e2211-e2221
pubmed: 30446596
BMC Neurol. 2022 Dec 31;22(1):512
pubmed: 36585619
Cephalalgia. 2022 Jul;42(8):705-714
pubmed: 35301884
Neurol Sci. 2023 Jul;44(7):2455-2463
pubmed: 36826456
J Headache Pain. 2021 May 3;22(1):35
pubmed: 33941080
J Headache Pain. 2023 Aug 4;24(1):103
pubmed: 37542222
Front Neurol. 2022 Jan 06;12:788159
pubmed: 35069416
J Headache Pain. 2022 Jul 28;23(1):90
pubmed: 35896988
JAMA Neurol. 2018 Feb 1;75(2):187-193
pubmed: 29255900
BMC Neurol. 2018 Nov 9;18(1):188
pubmed: 30413151